Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Exelixis, Inc. - Common Stock (NQ: EXEL )

37.20 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3
Open 37.20
Bid (Size) 36.28 (2)
Ask (Size) 38.63 (1)
Prev. Close 37.20
Today's Range 37.20 - 37.20
52wk Range 20.14 - 40.02
Shares Outstanding 315,048,788
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Is This The Beginning? Insights On Bearish Distribution Patterns
Discover the characteristics of a bearish distribution and the criteria the S&P 500 needs for a technical rally. 
Via Talk Markets
Topics Stocks Stocks / Equities
Exposures US Equities
Why EXELIXIS INC (NASDAQ:EXEL) qualifies as a high growth stock.
A fundamental and technical analysis of (NASDAQ:EXEL): EXELIXIS INC (NASDAQ:EXEL) may be suited for high growth investing, we'll explore why in this article. 
Via Chartmill

Performance

YTD
+9.61%
+9.61%
1 Month
+11.04%
+11.04%
3 Month
+5.03%
+5.03%
6 Month
+39.69%
+39.69%
1 Year
+63.95%
+63.95%

More News

Read More
Peering Into Exelixis's Recent Short Interest
Via Benzinga
Exelixis to Webcast Fireside Chats at Upcoming Investor Conferences in March
From Exelixis, Inc.
Via Business Wire
This Conagra Brands Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
Via Benzinga
Why Exelixis Stock Trounced the Market on Thursday
Via The Motley Fool
A Glimpse Into The Expert Outlook On Exelixis Through 21 Analysts
Via Benzinga
2 Stocks to Buy With Less Than $40
Via The Motley Fool
Why Is Cancer-Focused Exelixis Stock Trading Higher On Friday?
Via Benzinga
Exelixis Announces a Newly Authorized $500 Million Stock Repurchase Program
From Exelixis, Inc.
Via Business Wire
Don't overlook NASDAQ:EXEL—a stock with solid growth prospects and a reasonable valuation.
Via Chartmill
Top 5 Biotech Stocks That Got Most Retail Buzz Last Week
Via Stocktwits
Bullish Setups
Via Talk Markets
Topics Stocks / Equities
Exelixis Announces Final Five-Year Follow-up Results from CheckMate -9ER Trial Evaluating CABOMETYX® (cabozantinib) in Combination with Opdivo® (nivolumab) in Patients with Advanced Kidney Cancer at ASCO GU 2025
From Exelixis, Inc.
Via Business Wire
Exelixis to Participate in the Citi 2025 Virtual Oncology Leadership Summit
From Exelixis, Inc.
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Exelixis (EXEL) Q4 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Exelixis Posts 63.7% Profit Surge
Via The Motley Fool
Exelixis Announces Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
NASDAQ:EXEL: good value for what you're paying.
Via Chartmill
Exelixis to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025
From Exelixis, Inc.
Via Business Wire
Earnings Scheduled For February 11, 2025
Via Benzinga
Investors should take note of NASDAQ:EXEL, a growth stock that remains attractively priced.
Via Chartmill
Abbott To Rally Over 26%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
This Twilio Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.